Cognitive Behavioural Therapy for Nightmares for Patients with Persecutory Delusions (Nites): An Assessor-Blind, Pilot Randomized Controlled Trial.


Journal

Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 28 5 2019
medline: 30 9 2020
entrez: 28 5 2019
Statut: ppublish

Résumé

Nightmares are relatively common in patients experiencing psychosis but rarely assessed or treated. Nightmares may maintain persecutory delusions by portraying fears in sensory-rich detail. We tested the potential benefits of imagery-focused cognitive behavioural therapy (CBT) for nightmares on nightmare severity and persecutory delusions. This assessor-blind parallel-group pilot trial randomized 24 participants with nightmares and persecutory delusions to receive CBT for nightmares delivered over 4 weeks in addition to treatment as usual (TAU) or TAU alone. Assessments were at 0, 4 (end of treatment), and 8 weeks (follow-up). Feasibility outcomes assessed therapy uptake, techniques used, satisfaction, and attrition. The primary efficacy outcome assessed nightmare severity at week 4. Analyses were intention to treat, estimating treatment effect with 95% confidence intervals (CIs). All participants offered CBT completed therapy (mean [SD], 4.8 [0.6] sessions) with high satisfaction, and 20 (83%) participants completed all assessments. Compared with TAU, CBT led to large improvements in nightmares (adjusted mean difference = -7.0; 95% CI, -12.6 to -1.3; CBT for nightmares is feasible and may be efficacious for treating nightmares and comorbid insomnia for patients with persecutory delusions. It shows promise on paranoia but potentially not on suicidal ideation.

Identifiants

pubmed: 31129983
doi: 10.1177/0706743719847422
pmc: PMC6783669
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

686-696

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Références

Sleep. 2012 Aug 01;35(8):1153-61
pubmed: 22851811
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
J Clin Sleep Med. 2010 Aug 15;6(4):389-401
pubmed: 20726290
Bipolar Disord. 2011 Nov-Dec;13(7-8):651-61
pubmed: 22085478
Schizophr Bull. 2006 Apr;32(2):366-77
pubmed: 16237200
Trends Cogn Sci. 2015 Oct;19(10):590-602
pubmed: 26412097
Sleep. 2014 Feb 01;37(2):409-17
pubmed: 24497669
Sleep Med Rev. 2013 Apr;17(2):143-52
pubmed: 23046846
Clin Psychol Rev. 2012 Aug;32(6):566-74
pubmed: 22819998
J Clin Psychopharmacol. 2018 Dec;38(6):618-621
pubmed: 30335633
Sleep. 2001 Nov 1;24(7):844-7
pubmed: 11683487
Can J Psychiatry. 2015 Aug;60(8):354-61
pubmed: 26454557
Lancet Psychiatry. 2017 Oct;4(10):749-758
pubmed: 28888927
Clin Psychol Rev. 2013 Feb;33(1):146-55
pubmed: 23186732
Anesthesiology. 2008 May;108(5):812-21
pubmed: 18431116
Schizophr Res. 2006 Jul;85(1-3):288-95
pubmed: 16626943
Psychol Med. 2008 Jan;38(1):101-11
pubmed: 17903336
Schizophr Bull. 2019 Mar 7;45(2):287-295
pubmed: 30202909
Schizophr Bull. 2018 Apr 6;44(3):662-671
pubmed: 28981834
BMJ Open. 2014 Mar 18;4(3):e004183
pubmed: 24643168
Lancet Psychiatry. 2017 Sep;4(9):725-732
pubmed: 28396067
J Consult Clin Psychol. 1979 Apr;47(2):343-52
pubmed: 469082
J Clin Psychiatry. 2010 Nov;71(11):1440-6
pubmed: 21114949
Sleep. 2016 Jun 01;39(6):1275-82
pubmed: 27091530
J Behav Ther Exp Psychiatry. 2007 Dec;38(4):297-305
pubmed: 18035331
Soc Psychiatry Psychiatr Epidemiol. 2017 Sep;52(9):1123-1133
pubmed: 28712041
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Psychiatry Res. 2016 Dec 30;246:453-460
pubmed: 27792974
Sleep. 2006 Oct;29(10):1313-9
pubmed: 17068985
Br J Clin Psychol. 2000 Nov;39(4):407-14
pubmed: 11107494
Chest. 2016 Mar;149(3):631-8
pubmed: 26378880
Clin Psychol Rev. 2010 Apr;30(3):349-62
pubmed: 20116915
Conscious Cogn. 2011 Dec;20(4):998-1008
pubmed: 21075010
Sleep. 2016 Jan 01;39(1):173-81
pubmed: 26350467
Behav Ther. 2016 Sep;47(5):702-719
pubmed: 27816082
Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39
pubmed: 16004657

Auteurs

Bryony Sheaves (B)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Emily A Holmes (EA)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Department of Psychology, Uppsala University, Sweden.
Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden.

Stephanie Rek (S)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.

Kathryn M Taylor (KM)

Nuffield Department of Primary Care Health Sciences, Primary Care Clinical Trials Unit, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK.

Alecia Nickless (A)

Nuffield Department of Primary Care Health Sciences, Primary Care Clinical Trials Unit, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK.

Felicity Waite (F)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Anne Germain (A)

Department of Psychiatry, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Colin A Espie (CA)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Paul J Harrison (PJ)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Russell Foster (R)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Daniel Freeman (D)

Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
Nuffield Department of Primary Care Health Sciences, Primary Care Clinical Trials Unit, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH